Cardiology Research and Practice disease,” Kidney International, vol. 74, no. 12, pp. 1610–1616, 2008. [32] G. Y. Oudit, G. C. Liu, J. Zhong et al., “Human recombinant ACE2 reduces the progression of diabetic nephropathy,” Diabetes, vol. 59, no. 2, pp. 529–538, 2010. [33] D. W. Wong, G. Y. Oudit, H. Reich et al., “Loss of angio- tensin-converting enzyme-2 (ACE2) accelerates diabetic kid- ney injury,” American Journal of Pathology, vol. 171, no. 2, pp. 438–451, 2007. [34] S. M. Bindom, C. P. Hans, H. Xia, A. H. Boulares, and E. Lazartigues, “Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice,” Diabetes, vol. 59, no. 10, pp. 2540–2548, 2010. [35] M. J. Niu, J. K. Yang, S. S. Lin, X. J. Ji, and L. M. Guo, “Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice,” Endocrine, vol. 34, no. 1–3, pp. 56–61, 2008. [36] I. Castan-Laurell, C. Dray, C. Attane´, T. Duparc, C. Knauf, and P. Valet, “Apelin, diabetes, and obesity,” Endocrine, vol. 40, no. 1, pp. 1–9, 2011. [37] G. Erdem, T. Dogru, I. Tasci, A. Sonmez, and S. Tapan, “Low plasma apelin levels in newly diagnosed type 2 diabetes mel- litus,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 5, pp. 289–292, 2008. [38] F. Soriguer, L. Garrido-Sanchez, S. Garcia-Serrano et al., “Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus,” Obesity Surgery, vol. 19, no. 11, pp. 1574–1580, 2009. [39] J. C. Zhong, X. Y. Yu, Y. Huang, L. M. Yung, C. W. Lau, and S. G. Lin, “Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice,” Cardiovascular Research, vol. 74, no. 3, pp. 388–395, 2007. [40] K. Rittig, U. Hildebrandt, C. Thamer et al., “Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes,” Experimental and Clinical Endocrinology and Dia- betes, vol. 119, no. 6, pp. 358–361, 2011. [41] T. Duparc, A. Colom, P. D. Cani et al., “Central apelin controls glucose homeostasis via a nitric oxide-dependent pathway in mice,” Antioxidants and Redox Signaling, vol. 15, no. 6, pp. 1477–1496, 2011. [42] H. Chen, C. Zheng, X. Zhang et al., “Apelin alleviates dia- betes-associated endoplasmic reticulum stress in the pan- creas of akita mice,” Peptides, vol. 32, no. 8, pp. 1634–1639, 2011. [43] C. Dray, C. Knauf, D. Daviaud et al., “Apelin stimulates glucose utilization in normal and obese insulin-resistant mice,” Cell Metabolism, vol. 8, no. 5, pp. 437–445, 2008. [44] J. C. Zhong, X. Y. Yu, Q. X. Lin et al., “Enhanced angiotensin converting enzyme 2 regulates the insulin/akt signalling pathway by blockade of macrophage migration inhibitory factor expression,” British Journal of Pharmacology, vol. 153, no. 1, pp. 66–74, 2008. [45] J. Zhong, D. Guo, C. B. Chen et al., “Prevention of angiot- ensin II-mediated renal oxidative stress, inﬂammation, and ﬁbrosis by angiotensin-converting enzyme 2,” Hypertension, vol. 57, no. 2, pp. 314–322, 2011. [46] F. Lovren, Y. Pan, A. Quan et al., “Angiotensin converting enzyme-2 confers endothelial protection and attenuates ath- erosclerosis,” American Journal of Physiology, vol. 295, no. 4, pp. H1377–H1384, 2008. 9 [47] S. E. Thatcher, X. Zhang, D. A. Howatt et al., “Angiotensin- converting enzyme 2 deﬁciency in whole body or bone marrow-derived cells increases atherosclerosis in low-density lipoprotein receptor−/− mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 4, pp. 758–765, 2011. [48] C. Zhang, Y. X. Zhao, Y. H. Zhang et al., “Angiotensin- converting enzyme 2 attenuates atherosclerotic lesions by tar- geting vascular cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 36, pp. 15886–15891, 2010. [49] B. Dong, C. Zhang, J. B. Feng et al., “Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclero- sis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 7, pp. 1270–1276, 2008. [50] A. M. El-Shehaby, M. M. El-Khatib, A. A. Battah, and A. R. Roshdy, “Apelin: a potential link between inﬂammation and cardiovascular disease in end stage renal disease patients,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 70, no. 6, pp. 421–427, 2010. [51] N. J. Leeper, M. M. Tedesco, Y. Kojima et al., “Apelin pre- vents aortic aneurysm formation by inhibiting macrophage inﬂammation,” American Journal of Physiology, vol. 296, no. 5, pp. H1329–H1335, 2009. [52] M. Sawane, H. Kidoya, F. Muramatsu, N. Takakura, and K. Kajiya, “Apelin attenuates UVB-induced edema and inﬂam- mation by promoting vessel function,” American Journal of Pathology, vol. 179, no. 6, pp. 2691–2697, 2011. [53] S. L. Pitkin, J. J. Maguire, R. E. Kuc, and A. P. Davenport, “Modulation of the apelin/APJ system in heart failure and atherosclerosis in man,” British Journal of Pharmacology, vol. 160, no. 7, pp. 1785–1795, 2010. [54] Y. Feng, L. Ni, H. Wan et al., “Overexpression of ACE2 produces antitumor eﬀects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro,” Oncology Reports, vol. 26, no. 5, pp. 1157–1164, 2011. [55] Y. Feng, H. Wan, J. Liu et al., “The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogen- esis in non-small cell lung cancer,” Oncology Reports, vol. 23, no. 4, pp. 941–948, 2010. [56] C. Tiani, E. Garcia-Pras, M. Mejias et al., “Apelin signaling modulates splanchnic angiogenesis and portosystemic col- lateral vessel formation in rats with portal hypertension,” Journal of Hepatology, vol. 50, no. 2, pp. 296–305, 2009. [57] O. Kunduzova, N. Alet, N. Delesque-Touchard et al., “Apelin/ APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes,” The FASEB Journal, vol. 22, no. 12, pp. 4146–4153, 2008. [58] H. Kidoya, H. Naito, and N. Takakura, “Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia,” Blood, vol. 115, no. 15, pp. 3166–3174, 2010. [59] A. Kasai, Y. Ishimaru, T. Kinjo et al., “Apelin is a crucial fac- tor for hypoxia-induced retinal angiogenesis,” Arteriosclero- sis, Thrombosis, and Vascular Biology, vol. 30, no. 11, pp. 2182–2187, 2010. [60] M. Tendera, “The epidemiology of heart failure,” Journal of the Renin-Angiotensin-Aldosterone System, vol. 5, supplement 1, pp. S2–S6, 2004. [61] Z. Kassiri, J. Zhong, D. Guo et al., “Loss of angiotensin- converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction,” Circula- tion, vol. 2, no. 5, pp. 446–455, 2009. [62] S. Der Sarkissian, J. L. Grobe, L. Yuan et al., “Cardiac over- expression of angiotensin converting enzyme 2 protects the